产品
编 号：F479511
分子式：C50H72O14
分子量：897.1
分子式：C50H72O14
分子量：897.1
产品类型
规格
价格
是否有货
100μg
询价
询价
结构图
CAS No: 85079-48-7
产品详情
生物活性：
Brevetoxin-3 (PbTx-3) is a potent allosteric voltage-gated Na+?channel activator and has multiple active centers (A-ring lactone, C-42 of R side chain). Brevetoxin-3 (PbTx-3) has a high affinity to site 5 of the voltage-sensitive Na+?channels, inhibits the inactivation of Na+ channels and prolongs the mean open time of these channels. Brevetoxin-3 (PbTx-3) repeated exposures can lead to prolonged airway hyperresponsiveness (AHR) and lung inflammation.
体内研究：
Brevetoxin-3 (PbTx-3)(intratracheal instillation; 2.8 μg/kg; gestational days 15-18)?radioactivity is detected in placentas and fetuses within 0.5 hours. Concentrations of brevetoxin equivalents in fetuses are approximately 0.3 ng/g throughout the 48-h post-dosing, resulting in a calculated dose to fetuses of 19 ng/gh. Following brevetoxin infusion, concentration of brevetoxin equivalents in fetuses is 0.1 ng/g, lower than that present in most maternal tissues..Animal Model:Pregnant CD-1 mice
Dosage:2.8 μg/kg
Administration:Intratracheal instillation; 2.8 μg/kg; gestational days 15–18
Result:Demonstrated placental transport of brevetoxin or its metabolites following maternal acute exposure.?
体外研究：
Brevetoxin-3 (PbTx-3)(30-500 nM) produces a shift in activation to more negative membrane potentials whereby single-channel activity is observed under steady-state conditions (maintained depolarization at -50 mV).
Brevetoxin-3 (PbTx-3) is a potent allosteric voltage-gated Na+?channel activator and has multiple active centers (A-ring lactone, C-42 of R side chain). Brevetoxin-3 (PbTx-3) has a high affinity to site 5 of the voltage-sensitive Na+?channels, inhibits the inactivation of Na+ channels and prolongs the mean open time of these channels. Brevetoxin-3 (PbTx-3) repeated exposures can lead to prolonged airway hyperresponsiveness (AHR) and lung inflammation.
体内研究：
Brevetoxin-3 (PbTx-3)(intratracheal instillation; 2.8 μg/kg; gestational days 15-18)?radioactivity is detected in placentas and fetuses within 0.5 hours. Concentrations of brevetoxin equivalents in fetuses are approximately 0.3 ng/g throughout the 48-h post-dosing, resulting in a calculated dose to fetuses of 19 ng/gh. Following brevetoxin infusion, concentration of brevetoxin equivalents in fetuses is 0.1 ng/g, lower than that present in most maternal tissues..Animal Model:Pregnant CD-1 mice
Dosage:2.8 μg/kg
Administration:Intratracheal instillation; 2.8 μg/kg; gestational days 15–18
Result:Demonstrated placental transport of brevetoxin or its metabolites following maternal acute exposure.?
体外研究：
Brevetoxin-3 (PbTx-3)(30-500 nM) produces a shift in activation to more negative membrane potentials whereby single-channel activity is observed under steady-state conditions (maintained depolarization at -50 mV).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备